



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 SEPT 2012

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 9/30/2012 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 9/30/2011 RM'000	CURRENT YEAR TO DATE 9/30/2012 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 9/30/2011 RM'000
Revenue	29,521	36,767	99,932	105,096
Cost of Sales	(15,790)	(19,802)	(53,890)	(59,030)
Gross Profit	13,731	16,965	46,042	46,066
Other operating income	4	50	593	178
Distribution costs	(3,272)	(3,102)	(9,242)	(8,227)
Administration expenses	(1,658)	(3,349)	(8,984)	(9,434)
Other operating expenses	(353)	(771)	(1,938)	(1,882)
Profit from operations	8,452	9,793	26,471	26,701
Finance income	4	44	89	323
Finance costs	(64)	(111)	(262)	(132)
Profit before taxation	8,392	9,726	26,298	26,892
Taxation	(1,950)	(2,205)	(6,281)	(6,515)
Profit after tax for the period	6,442	7,521	20,017	20,377
Other comprehensive income	-	-	-	-
Total other comprehensive income for the period	6,442	7,521	20,017	20,377
Profit attributable to:				
Shareholders of the Company	6,442	7,521	20,017	20,377
Minority interest	-	-	-	-
	6,442	7,521	20,017	20,377
Total other comprehensive income attributable to:				
Shareholders of the Company	6,442	7,521	20,017	20,377
Minority interest	-	-	-	-
	6,442	7,521	20,017	20,377
Earnings per share (sen)				
Basic (based on weighted average)	4.64	5.42	14.42	14.68
Diluted (based on weighted average)	4.64	5.42	14.42	14.68

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPT 2012

	AS AT 30/9/2012 RM'000	AS AT 31/12/2011 RM'000 Restated (*)	AS AT 1/1/2011 RM'000 Restated (*)
ASSETS			
Property, Plant and Equipment	96,679	95,977	100,249
Investment properties	5,720	5,720	-
Total non-current assets	<u>102,399</u>	<u>101,697</u>	<u>100,249</u>
Inventories	47,558	45,124	34,003
Trade & Other Receivables	36,397	36,911	34,804
Amount Due From Related Company	1,971	769	951
Current tax assets	2,437	2,695	-
Assets classified as held for sale	-	1,740	1,740
Cash & Cash Equivalents	4,777	8,584	24,732
Total current assets	<u>93,140</u>	<u>95,823</u>	<u>96,230</u>
Total Assets	<u><u>195,539</u></u>	<u><u>197,520</u></u>	<u><u>196,479</u></u>
EQUITY			
Share Capital	69,739	69,739	69,739
Reserves	13,720	13,720	13,720
Retained earnings	87,484	82,564	75,988
Treasury Shares	(1,578)	(1,578)	(1,578)
Total Equity	<u>169,365</u>	<u>164,445</u>	<u>157,869</u>
LIABILITIES			
Deferred Tax Liability	5,152	5,584	3,821
Borrowings	-	2,082	10,416
Total non-current liabilities	<u>5,152</u>	<u>7,666</u>	<u>14,237</u>
Trade & Other Payables	15,045	14,304	13,509
Amount due to related company	1,046	2,005	1,324
Provision	766	766	850
Taxation	-	-	356
Borrowings	4,165	8,334	8,334
Total current liabilities	<u>21,022</u>	<u>25,409</u>	<u>24,373</u>
Total Liabilities	<u><u>26,174</u></u>	<u><u>33,075</u></u>	<u><u>38,610</u></u>
Total Equity & Liabilities	<u><u>195,539</u></u>	<u><u>197,520</u></u>	<u><u>196,479</u></u>
Net assets per share (RM)	1.21	1.18	1.13

* Upon adoption of MFRS, the Condensed Consolidated Statement of Financial Positions at 31 December 2011 and 1 January 2011 have been restated accordingly.

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 SEPT 2012

	30 Sept 2012	30 Sept 2011
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	26,298	26,892
Adjustments for:		
Depreciation of property, plant and equipment	5,096	4,060
Interest income	(89)	(323)
Finance costs	262	132
Gain on disposal of property, plant and equipment	(611)	-
<i>Operating profit before changes in working capital</i>	<u>30,956</u>	<u>30,761</u>
Increase/(decrease) in inventories	(2,434)	(6,397)
Increase/(decrease) in receivables, deposits and prepayments	(332)	(9,205)
Increase/(decrease) in payables and accruals	(574)	1,400
<i>Cash generated from operations</i>	<u>27,616</u>	<u>16,559</u>
Finance costs paid	(262)	(132)
Interest income	89	323
Income tax paid	(6,456)	(6,673)
Net cash generated from operating activities	<u>20,987</u>	<u>10,077</u>
Cash flows from investing activities		
Acquisition of property, plant and equipment	(5,798)	(5,164)
Proceed from disposal of property, plant and equipment	2,352	-
Net cash used in investing activities	<u>(3,446)</u>	<u>(5,164)</u>
Cash flows from financing activities		
Repayment of borrowings	(6,251)	(6,251)
Dividends paid to shareholders of the Company	(15,097)	(15,270)
Net cash used in financing activities	<u>(21,348)</u>	<u>(21,521)</u>
Net decrease in cash and cash equivalents	(3,807)	(16,608)
Cash and cash equivalents at 1 January	8,584	24,732
Cash and cash equivalents as at 30 Sept	<u>4,777</u>	<u>8,124</u>

(i) Cash and cash equivalents comprise:

	RM '000	RM '000
Cash and bank balances	4,615	3,867
Fixed deposits placed with licensed financial institutions	162	4,257
	<u>4,777</u>	<u>8,124</u>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)